Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application

Li, Shuang-long and Zhu, Yong-liang and Zhang, Yi and Liu, Shu-han and Wang, Xiang-die and Qiu, Xiang-jun (2020) Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. International Journal of Analytical Chemistry, 2020. pp. 1-7. ISSN 1687-8760

[thumbnail of 5084127.pdf] Text
5084127.pdf - Published Version

Download (1MB)

Abstract

In our research, a straightforward UPLC-MS/MS method, with diazepam as the internal standard (IS), was proposed and acknowledged to determine the concentrations of enasidenib in rat plasma. When preparing the sample, we used acetonitrile for protein precipitation. The gradient elution method was used, and the mobile phase was acetonitrile and 0.1% formic acid. Diazepam was used as the IS. We used the Acquity UPLC BEH C18 column to separate enasidenib and IS. Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be m/z 474.2 ⟶ 456.1 and m/z 474.2 ⟶ 267.0, and the IS mass transfer pairs were m/z 285.0 ⟶ 154.0. Enasidenib had good linearity (r2 = 0.9985) in the concentration range of 1.0–1000 ng/mL. Besides, the values of intraday and interday precision were 2.25–8.40% and 3.94–5.46%, respectively, and the range of the accuracy values varied from −1.44 to 2.34%. Matrix effect, extraction recovery, and stability were compliant with FDA approval guidelines in terms of bioanalytical method validation. We had established a new method that had been applied to the pharmacokinetic study of enasidenib in rats.

Item Type: Article
Subjects: STM Digital Library > Chemical Science
Depositing User: Unnamed user with email support@stmdigitallib.com
Date Deposited: 05 Jan 2023 10:15
Last Modified: 20 Apr 2024 08:04
URI: http://archive.scholarstm.com/id/eprint/11

Actions (login required)

View Item
View Item